155
Participants
Start Date
June 3, 2021
Primary Completion Date
May 10, 2023
Study Completion Date
September 8, 2025
Valemetostat Tosylate
Oral administration of valemetostat tosylate at a dose of 200 mg once daily starting at Cycle 1, Day 1 (continuous for 28-day cycles), until disease progression or unacceptable toxicity
Epworth Healthcare, Richmond
National Taiwan University Hospital - Hematology And Oncology, Taipei
Memorial Sloan-Kettering Cancer Center at Memorial Hospital, New York
Weill Cornell Medicine, New York
University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia
PO San Gerardo, ASST Monza, Monza
CHU de Dijon, Dijon
ASST Papa Giovanni XXIII - Medicina Trasfusionale ed Ematologia - Bergamo, Bergamo
Duke Cancer Center, Durham
Hospital Universitario Fundación Jiménez Díaz, Madrid
Hospital Universitario La Paz, Madrid
Emory University Hospital - Winship Cancer Institute, Atlanta
Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole), Toulouse
Chang Gung Medical Foundation - LinKou Chang Gung Memorial Hospital - Hematology and Oncology - Hematology and Oncology, Taoyuan
A.O.di Bologna Policl.S.Orsola, Bologna
Hospital Universitario Virgen del Rocio, Seville
Mayo Clinic - Rochester, Rochester
CHRU de Lille - Hôpital Claude Huriez - Maladies du Sang, Lille
Northwestern University - Feinberg School of Medicine, Chicago
Washington University School of Medicine, St Louis
Centre Lyon Berard - Medical Oncology, Lyon
Centre Hospitalier Lyon Sud - Hématologie, Pierre-Bénite
National Cheng Kung University Hospital - Internal Medicine, Tainan City
APHP - Hopital Saint Louis, Paris
Hôpital Necker, Paris
University Of Colorado Cancer Center, Aurora
Fondazione Pascale, IRCCS, Istituto Nazionale dei Tumori, Napoli
Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital - Hemato-Oncology, Kaohsiung City
City Of Hope National Medical Center, Duarte
University of California San Francisco, San Francisco
Stanford University Medical Center - Cancer Clinical Trials Office - ONCOLOGY, Palo Alto
Dana Farber Cancer Institute, Boston
Hackensack University Medical Center - John Theurer Cancer Center, Hackensack
BC Cancer - Vancouver Centre, Vancouver
Ottawa Hospital Research Institute, Ottawa
University Health Network Princess Margaret Hospital, Toronto
Universitätsklinikum Halle (Saale) - Klinik und Poliklinik für Innere Medizin IV, Halle
Ospedale S.Maria della Misericordia, AO di Perugia, Università degli Studi di Perugia, Perugia
National Hospital Organization Nagoya Medical Center - Hematology, Nagoya
Nagoya City University Hospital, Nagoya
National Cancer Center Hospital East, Kashiwa
Hokkaido University Hospital - Medical Oncology Center, Sapporo
National Cancer Center Hospital, Chuo Ku
Kyushu University Hospital, Fukuoka
Kagoshima University Hospital, Kagoshima
University Hospital - Kyoto Prefectural University of Medicine, Kyoto
Nagasaki University Hospital, Nagasaki
Okayama University Hospital, Okayama
Leids Universitair Medisch Centrum (LUMC) (Leiden University Medical Center), Leiden
Universiteit Maastricht Academisch Ziekenhuis Maastricht, Maastricht
Severance Hospital, Yonsei University Health System, Seoul
Seoul National University Hospital - Department of Internal, Seoul
Asan Medical Center - Oncology, Seoul
Samsung Medical Center - Hematology-Oncology, Seoul
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul
ICO Hospital Duran i Reynals, Barcelona
Hospital Universitario Vall d'Hebrón, Barcelona
University College London Hospital, London
Nottingham City Hospital - Clinical Haematology, Nottingham
Churchill Hospital, Oxford
Lead Sponsor
Daiichi Sankyo
INDUSTRY